Smoke Science & Product Technology (SSPT) Study Groups for CORESTA
Some of British American Tobacco’s top scientists are on their way to the Joint Meeting of the Smoke Science & Product Technology (SSPT) Study Groups for CORESTA in Kitzbuhel, Austria for the 8th-12th October to present some of our latest research and the quality science that we have been developing. For anyone interested in what BAT will be presenting,here is a timetable of BAT's contributions to the scientific discussions:
Tuesday 10th October:
09:10-09:30 – Mike McEwan – ST25 – A clinical study in Japanese smokers investigating changes in exposure to cigarette smoke chemicals who switch to using a tobacco heating product for a five-day period
10:10-10:30 – Ian Fearon – ST28 – Nicotine pharmacokinetics of electronic cigarettes: a review of the literature
Thursday 12th October:
11:50-12:10 – David Thorne – ST64 – A novel approach for the screening of e-cigarette aerosols using an Ames whole aerosol assay
Tuesday 10th October – 14:00-16:00
Krishna Prasad – STPOST34 – Optical method for estimating mouth level exposure from conventional cigarettes and next generation tobacco and nicotine products
Mark Taylor – STPOST48 – The in vitro biological assessment of a novel hybrid tobacco product and comparison with a cigarette smoke.
Tomasz Jaunky – STPOST49 – In vitro assessment of a novel prototype e-cigarette
Marianna Gaca – STPOST50 – Vascular endothelial oxidative stress leading to hypertension: development of an AOP using in vitro assays.
Andrew Baxter – STPOST51 – RNA-seq-based toxicogenomics shows limited impact of e-cigarette vapour on airway cells compared with cigarette smoke when matching for nicotine delivery
All posters and presentations will be uploaded to www.bat-science.com after the conference to publicly share our science and add to our online catalogue of high quality, cutting-edge research.
If anyone is interest in the full proceedings of the SSPT Meeting for CORESTA, please visit the conference website at: http://www.sspt2017.org/
Notes to Editors
About British American Tobacco: British American Tobacco is a global tobacco and Next Generation Product company with brands sold in more than 200 markets. It employs more than 50,000 people worldwide and has over 200 brands in its portfolio, with its cigarettes chosen by one in eight of the world’s one billion smokers. Leading global brands include Dunhill, Kent, Pall Mall and Lucky Strike.
About Next Generation Products (NGP): Next Generation Products is part of the British American Tobacco Group and is focused on developing and delivering high-quality alternative nicotine and tobacco products for adult consumers in the key areas of Vapour, Oral and Tobacco Heating Products. For more information see www.goVype.com and www.bat-science.com.
About Tobacco Harm Reduction: The only way to avoid the risks associated with tobacco use is not to consume tobacco at all, and the best way to reduce the risks is to stop using tobacco. However, the concept of harm reduction is increasingly being considered in relation to tobacco use. Harm reduction is about finding practical ways to minimise the health impact of an inherently risky activity or behaviour, without seeking to stop it entirely. It is a key element of BAT’s business strategy and is being discussed by some regulators. We think it’s important to work towards producing consumer-acceptable, potentially reduced risk products. We believe that tobacco regulatory policies should include harm reduction approaches for the millions of adults globally who will continue to consume tobacco products.
The Public Health Impact of e-cigarettes: Many in the public health community believe e-cigarettes offer great potential for contributing to tobacco harm reduction policies. A 2018 updated evidence review by Public Health England*, an executive body of the UK Department of Health, concludes that vaping is around 95% less harmful than smoking cigarettes. The UK’s Royal College of Physicians have said that the public can be reassured that e-cigarettes are much safer than smoking and that they should be widely promoted as a substitute for smoking.
For more information: email Joanna_Hunt@bat.com or call +44 (0)7858 375461